etravirine has been researched along with raltegravir potassium in 62 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (raltegravir potassium) | Trials (raltegravir potassium) | Recent Studies (post-2010) (raltegravir potassium) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 1,238 | 243 | 879 |
| Protein | Taxonomy | etravirine (IC50) | raltegravir potassium (IC50) |
|---|---|---|---|
| Translocator protein | Rattus norvegicus (Norway rat) | 0.13 | |
| Integrase | Human immunodeficiency virus 1 | 0.0494 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (27.42) | 29.6817 |
| 2010's | 37 (59.68) | 24.3611 |
| 2020's | 8 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Boffito, M; Mallon, PW; Winston, A | 1 |
| Susman, E | 1 |
| Temesgen, Z | 1 |
| Boyle, BA; Cohen, CJ; Elion, R; Frank, I; Moyle, GJ; Sax, P | 1 |
| Bruzzone, B; Di Biagio, A; Icardi, G; Rosso, R; Rusconi, S; Viganò, O; Viscoli, C | 1 |
| Taéron, C | 1 |
| Barber, T; Hughes, A; Nelson, M | 1 |
| Baietto, L; Bonora, S; D'Avolio, A; Di Perri, G; Oddone, V; Sciandra, M; Siccardi, M; Simiele, M | 1 |
| Anderson, MS; Hanley, W; Hoetelmans, RM; Iwamoto, M; Kakuda, TN; Kost, JT; Miller, J; Stoltz, R; Stone, JA; Wagner, JA; Wenning, LA | 1 |
| Vallone, A; Vento, S | 1 |
| Arazo Garcés, P; Omiste Sanvicente, T | 1 |
| Barreiro, P; Briz, V; de Mendoza, C; Garrido, C; Morello, J; Poveda, E; Soriano, V | 1 |
| Bregigeon, S; Drogoul, MP; Lacarelle, B; Martin, IP; Ménard, A; Mokthari, S; Solas, C; Tamalet, C | 1 |
| Arribas, JR | 1 |
| Bollens, D; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Pialoux, G; Piketty, C; Roquebert, B; Taburet, AM; Yazdanpanah, Y | 1 |
| Aumaître, H; Blanche, S; Chaix, ML; Firtion, G; Frange, P; Rabaud, C; Reliquet, V; Tamalet, C; Thuret, I; Tricoire, J | 1 |
| Giocanti, M; Lacarelle, B; Paccou, A; Quaranta, S; Solas, C; Woloch, C | 1 |
| Castagna, A; De Wit, S; Florence, E; Hill, A; Marks, S; Ribera, E; van Delft, Y; Vanaken, H | 1 |
| Appelbaum, JS; Bellman, P; Gathe, J; Gottlieb, MS; Hoogstoel, A; Lalezari, J; Nijs, S; Ryan, R; Sension, MG; Towner, W; Van Solingen-Ristea, R; Witek, J; Wohlfeiler, M | 1 |
| Fujii, T; Hosoya, N; Iwamoto, A; Kawana-Tachikawa, A; Kikuchi, T; Koga, M; Koibuchi, T; Miura, T; Miyazaki, N; Nakamura, H; Odawara, T | 1 |
| Antoniou, T; Bitnun, A; Brophy, J; Jaworsky, D; Loutfy, MR; Samson, L; Thompson, C; Yudin, MH | 1 |
| Bailey, JR; Gallant, JE; Pham, PA; Reiss, KA | 1 |
| Bravo, I; Clotet, B; Domingo, P; Ferrer, E; Imaz, A; Llibre, JM; Podzamczer, D; Ribera, E; Santos, JR; Videla, S | 1 |
| Bigoloni, A; Castagna, A; Cossarini, F; Della Torre, L; Galli, A; Galli, L; Lazzarin, A; Nicola, G; Nozza, S; Pogliaghi, M; Salpietro, S; Tambussi, G | 1 |
| Cattaneo, D; Gervasoni, C | 1 |
| Beijnen, JH; Huitema, AD; Mulder, JW; Ter Heine, R; van Gorp, EC; Wagenaar, JF | 1 |
| Bonora, S; Calcagno, A; Castagna, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Lazzarin, A; Nozza, S | 1 |
| Do, VT; Fulco, PP; Higginson, RT | 1 |
| Dronda, F; García-Blázquez, V; Lourido-García, D; Vicente-Bártulos, A | 1 |
| Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Rami, A; Vittecoq, D; Yazdanpanah, Y; Yeni, P | 1 |
| Acosta, EP; Fletcher, CV; Moore, R; Sandkovsky, U; Swindells, S | 1 |
| Bigoloni, A; Carini, E; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Piatti, P; Salpietro, S; Spagnuolo, V; Vinci, C | 1 |
| Albanese, A; Asmuth, DM; Hayes, T; Knight, TH; Ma, ZM; Mann, S; Melcher, GP; Miller, CJ; Pollard, RB; Troia-Cancio, P; Yotter, T | 1 |
| Agher, R; Calin, R; Katlama, C; Paris, L; Peytavin, G; Schneider, L; Simon, A; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Allavena, C; Bouquié, R; Dailly, E; Deslandes, G; Jolliet, P; Raffi, F | 1 |
| Antoniou, T; Brunetta, J; Halpenny, R; Hasan, S; Kovacs, C; La Porte, C; Loutfy, MR; Smith, G | 1 |
| Brun-Vézinet, F; Charpentier, C; Chêne, G; Colin, C; Descamps, D; Fagard, C; Jacomet, C; Katlama, C; Molina, JM; Taburet, AM; Visseaux, B; Yazdanpanah, Y | 1 |
| Lacombe, K; Surgers, L | 1 |
| Binet, L; Djerada, Z; Feliu, C; Gozalo, C; Lamiable, D; Marty, H; Millart, H; Robinet, A; Tournois, C; Vautier, D | 1 |
| Blanco, JL; Gatell, JM; González-Cordon, A; Laguno, M; Lonca, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Monteiro, P; Perez, I | 1 |
| Aarnoutse, R; Brüggemann, R; Burger, D; Krens, S; Robijns, K; Touw, D | 1 |
| Bigoloni, A; Carbone, A; Castagna, A; Chiappetta, S; Galli, L; Gianotti, N; Lazzarin, A; Nozza, S; Ripa, M; Spagnuolo, V; Tambussi, G | 1 |
| Bañón, S; Casado, JL; Moreno, A; Moreno, S; Rodriguez, MA | 1 |
| Charpentier, C; Descamps, D; Fagard, C; Harrigan, PR; Katlama, C; Lee, GQ; Molina, JM; Rodriguez, C; Storto, A; Visseaux, B; Yazdanpanah, Y | 1 |
| Andrade, A; Eron, JJ; Fichtenbaum, CJ; Gandhi, RT; Haubrich, RH; Johnson, VA; Klingman, KL; Mollan, KR; Na, L; Smeaton, L; Tashima, KT | 1 |
| Flores-Ruiz, E; Huerta-García, G; Mata-Marín, JA; Peregrino-Bejarano, L; Solórzano-Santos, F; Vazquez-Rosales, JG | 1 |
| Blakney, AK; Jiang, Y; Whittington, D; Woodrow, KA | 1 |
| Marzinke, MA; Parsons, TL | 1 |
| Borderi, M; Calza, L; Colangeli, V; Conti, M; Magistrelli, E; Mancini, R; Manfredi, R; Rossi, N; Viale, P | 1 |
| Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A | 1 |
| Calvez, V; Flandre, P; Marcelin, AG | 1 |
| Bruno, S; Corrigan, B; Letsie, M; Mthethwa, N; Mukui, I; Mulenga, L; Rakhmanina, N | 1 |
| Assoumou, L; Béniguel, L; Bouchaud, O; Capeau, J; Cardon, F; Costagliola, D; Fellahi, S; Gibowski, S; Katlama, C; Kolta, S; Marcelin, AG; Martinez, E; Molina, JM; Peytavin, G; Raffi, F; Reynes, J; Soulié, C; Valantin, MA | 2 |
| Avihingsanon, A; Bukuru, A; Cardoso, SW; Collier, AC; Faesen, S; Godfrey, C; Grinsztejn, B; Gross, R; Hogg, E; Hughes, MD; Kanyama, C; Kumarasamy, N; Makanga, M; Mave, V; Mellors, JW; Mngqibisa, R; Mohapi, L; Montalban, E; Mugyenyi, P; Nerette Fontain, S; Ritz, J; Salata, R; Samaneka, W; Santos, BR; Schooley, RT; Secours, R; Sugandhavesa, P; Valencia, J; van Schalkwyk, M; Wallis, CL; Wangari Ndege, B; Wieclaw, L | 1 |
| Abdi, B; Alloui, C; Assoumou, L; Avettand-Fenoel, V; Beniguel, L; Calvez, V; Costagliola, D; Delaugerre, C; Descamps, D; Ferre, V; Katlama, C; Marcelin, AG; Martinez, E; Montes, B; Nguyen, T; Peytavin, G; Reynes, J; Sayon, S; Soulie, C; Valantin, MA | 1 |
| Berruti, M; Del Puente, F; Di Biagio, A; Riccardi, N | 1 |
| Assoumou, L; Bastard, JP; Beniguel, L; Capeau, J; Costagliola, D; Farabos, D; Fellahi, S; Feve, B; Gibowski, S; Katlama, C; Lamaziere, A; Racine, C | 1 |
| Allavena, C; Assoumou, L; Bottero, J; Bouchaud, O; Dudoit, Y; Durand, A; Duvivier, C; Katlama, C; Lê, MP; Marcelin, AG; Montoya Ferrer, A; Palich, R; Peytavin, G; Soulie, C; Tubiana, R; Weiss, L | 1 |
| Al-Dhabi, NA; Arunagirinathan, N; Ignacimuthu, S; Indu, P; Rameshkumar, MR; Valan Arasu, M | 1 |
| Hamzah, L; Post, FA | 1 |
| Bellecave, P; Bonnet, F; Cazanave, C; Duffau, P; Hessamfar, M; Lazaro, E; Le Marec, F; Leleux, O; Neau, D; Nyamankolly, E; Perrier, A; Tumiotto, C; Vareil, MO; Wittkop, L | 1 |
6 review(s) available for etravirine and raltegravir potassium
| Article | Year |
|---|---|
The clinical pharmacology of antiretrovirals in development.
Topics: Animals; Anti-Retroviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Evaluation, Preclinical; Drug Interactions; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Protease Inhibitors; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2006 |
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Maraviroc; Nitriles; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome; Triazoles | 2008 |
[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].
Topics: Adult; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Darunavir; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Multicenter Studies as Topic; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viremia | 2008 |
[Role of the new molecules in antiretroviral therapy. Position of raltegravir].
Topics: Anti-HIV Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; Forecasting; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; Humans; Maraviroc; Nitriles; Peptide Fragments; Pyridazines; Pyridines; Pyrimidines; Pyrones; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Triazoles | 2008 |
Hepatoxicity of new antiretrovirals: a systematic review.
Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles | 2013 |
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2017 |
13 trial(s) available for etravirine and raltegravir potassium
| Article | Year |
|---|---|
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Integrase Inhibitors; HIV Seronegativity; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Treatment Outcome; Young Adult | 2008 |
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Resistance, Multiple, Viral; Female; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome | 2009 |
HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Immunosuppression Therapy; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome | 2010 |
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: analysis of the etravirine early access program in the United States.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; United States; Viral Load | 2010 |
Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Treatment Outcome; Triazoles; Viral Load | 2011 |
Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Endoscopy; Female; Gastrointestinal Tract; Humans; Immune Reconstitution Inflammatory Syndrome; Immunohistochemistry; Lymphocyte Activation; Lymphoid Tissue; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2012 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Darunavir; Drug Synergism; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
Topics: Anti-HIV Agents; Darunavir; DNA, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides | 2013 |
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Cell Count; Cyclohexanes; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Triazoles | 2014 |
Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; Humans; Male; Middle Aged; Nitriles; Peptide Fragments; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy | 2015 |
Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2019 |
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2020 |
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Middle Aged; Nitriles; Prospective Studies; Pyrimidines; Raltegravir Potassium; Treatment Outcome; Viral Load | 2021 |
43 other study(ies) available for etravirine and raltegravir potassium
| Article | Year |
|---|---|
AIDS 2006 - XVI International Conference. Time to deliver.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Anti-Infective Agents; CCR5 Receptor Antagonists; CD4 Antigens; Clinical Trials as Topic; Humans; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium | 2006 |
The latest in antiretroviral therapy.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Cyclohexanes; Darunavir; Drugs, Investigational; HIV Infections; HIV-1; Humans; Maraviroc; Nitriles; Organic Chemicals; Piperazines; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Receptors, Chemokine; Sulfonamides; Treatment Outcome; Triazoles | 2006 |
Advances in HIV therapeutics: the 14th CROI.
Topics: Acyclovir; Anti-HIV Agents; Circumcision, Male; Cyclohexanes; Dideoxynucleosides; Drug Interactions; Female; Hepatitis C; HIV Fusion Inhibitors; HIV Infections; Humans; Male; Maraviroc; Multicenter Studies as Topic; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Triazoles | 2007 |
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Nitriles; Organic Chemicals; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Treatment Outcome | 2008 |
[New drugs for HIV infection].
Topics: Anti-HIV Agents; Contraindications; Cyclohexanes; Darunavir; Drug Monitoring; HIV Infections; Humans; Maraviroc; Nitriles; Organic Chemicals; Patient Education as Topic; Patient Selection; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Triazoles | 2008 |
An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients.
Topics: Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sensitivity and Specificity | 2008 |
Darunavir-etravirine-raltegravir as salvage combination therapy in a heavily pretreated HIV-infected patient.
Topics: Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Salvage Therapy; Sulfonamides; Treatment Outcome | 2008 |
Raltegravir and etravirine are active against HIV type 1 group O.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Middle Aged; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Viral Load | 2009 |
Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.
Topics: Anti-HIV Agents; Drug Interactions; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2009 |
Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Darunavir; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.
Topics: Analytic Sample Preparation Methods; Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; HIV Protease Inhibitors; Humans; Limit of Detection; Microchemistry; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reproducibility of Results; Reverse Transcriptase Inhibitors; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Time Factors | 2009 |
Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Male; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Salvage Therapy; Sulfonamides; Viral Load | 2011 |
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
Topics: Adolescent; Adult; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Nitriles; Pregnancy; Pregnancy Complications, Infectious; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Sulfonamides; Treatment Outcome; Young Adult | 2010 |
Raltegravir-induced cerebellar ataxia.
Topics: Cerebellar Ataxia; Female; HIV Infections; HIV-1; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome | 2010 |
Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Darunavir; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Viral Load | 2011 |
Reply to 'Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'.
Topics: Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2011 |
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cyclohexanes; Female; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Salvage Therapy; Triazoles | 2011 |
Raltegravir dosage adjustment in HIV-infected patients receiving etravirine.
Topics: Anti-HIV Agents; Area Under Curve; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Glucuronosyltransferase; HIV Infections; HIV Integrase Inhibitors; Humans; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2011 |
[Leucoencephalopathy in a patient with type I human immunodeficiency virus (HIV-1) infection and symptoms of a hypertensive emergency].
Topics: Adult; Anti-HIV Agents; Brain Edema; Darunavir; Diagnosis, Differential; Dideoxynucleosides; Emergencies; Female; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Hypertension, Malignant; Hypertensive Encephalopathy; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Nitriles; Posterior Leukoencephalopathy Syndrome; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Tomography, X-Ray Computed; Toxoplasmosis, Cerebral | 2012 |
Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial.
Topics: Adult; Darunavir; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; RNA, Viral; Sulfonamides | 2012 |
Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Topics: Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Gastrostomy; HIV Infections; Humans; Male; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium | 2012 |
Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens.
Topics: Anti-HIV Agents; Blood Glucose; Cyclohexanes; Darunavir; Fasting; Glucose Tolerance Test; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Insulin; Insulin Resistance; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Treatment Outcome; Triazoles; Viral Load | 2012 |
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Viral Load | 2012 |
Pharmacokinetics of maraviroc, raltegravir, darunavir, and etravirine in the semen of HIV-infected men.
Topics: Anti-HIV Agents; Area Under Curve; Cyclohexanes; Darunavir; HIV Infections; Humans; Male; Maraviroc; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Semen; Sulfonamides; Triazoles | 2013 |
Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Topics: Adenine; Anti-Retroviral Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Humans; Maraviroc; Mass Spectrometry; Nitriles; Organophosphonates; Proline; Pyridazines; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Tandem Mass Spectrometry; Tenofovir; Time Factors; Triazoles | 2013 |
Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
Topics: Anti-HIV Agents; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Viral Load | 2014 |
Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/seru
Topics: Anti-Retroviral Agents; Clinical Laboratory Services; Darunavir; Drug Monitoring; Humans; Internationality; Nitriles; Pyridazines; Pyrimidines; Pyrrolidinones; Quality Control; Raltegravir Potassium; Sulfonamides | 2014 |
Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Viral Load | 2015 |
Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Longitudinal Studies; Mutation; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Treatment Outcome; Viral Load | 2015 |
Genotype-guided antiretroviral regimens in children with multidrug-resistant HIV-1 infection.
Topics: Adolescent; Anti-Retroviral Agents; CD4 Lymphocyte Count; Child; Darunavir; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Nitriles; Poverty; Pyridazines; Pyrimidines; Raltegravir Potassium; Retrospective Studies; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2016 |
Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Topics: Animals; Anti-HIV Agents; Bodily Secretions; Chromatography, Liquid; Cyclohexanes; Female; Limit of Detection; Linear Models; Macaca nemestrina; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Tandem Mass Spectrometry; Triazoles; Vagina | 2016 |
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Topics: Chromatography, Liquid; Cyclohexanes; Humans; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles | 2016 |
Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; Humans; Maintenance Chemotherapy; Male; Middle Aged; Nitriles; Prospective Studies; Pyridazines; Pyrimidines; Raltegravir Potassium; Treatment Outcome | 2017 |
Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; France; Gene Expression Regulation, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nitriles; Propensity Score; Pyridazines; Pyrimidines; Raltegravir Potassium; RNA, Viral; Viral Load | 2017 |
Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and/or Etravirine-based Antiretroviral Treatment.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Darunavir; Eswatini; Female; HIV Infections; HIV-1; Humans; Kenya; Lesotho; Lopinavir; Male; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zambia | 2018 |
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Topics: Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Nitriles; Pyridazines; Pyrimidines; Quality of Life; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2019 |
Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
Topics: Anti-HIV Agents; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium | 2020 |
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Nitriles; Pyrimidines; Raltegravir Potassium | 2020 |
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' res
Topics: Anti-HIV Agents; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium | 2020 |
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Topics: Antiviral Agents; Coronavirus Protease Inhibitors; COVID-19 Drug Treatment; Drug Repositioning; Heterocyclic Compounds, 3-Ring; Humans; Indinavir; Molecular Docking Simulation; Nitriles; Oxazines; Piperazines; Pyridines; Pyridones; Pyrimidines; Pyrones; Raltegravir Potassium; RNA-Dependent RNA Polymerase; SARS-CoV-2; Sulfonamides | 2020 |
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
Topics: Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin; Lamivudine; Menopause; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Raltegravir Potassium; Waist Circumference; Weight Gain | 2021 |
Long-term follow-up of HIV-1 multi-drug-resistant treatment-experienced participants treated with etravirine, raltegravir and boosted darunavir: towards drug-reduced regimen? ANRS CO3 Aquitaine Cohort 2007-2018.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Follow-Up Studies; HIV Infections; HIV-1; Humans; Raltegravir Potassium; Ritonavir; Treatment Outcome; Viral Load | 2023 |